NASDAQ:BCRX
BioCryst Pharmaceuticals Stock Earnings Reports
$9.97
+0.0500 (+0.504%)
At Close: May 09, 2025
BioCryst Pharmaceuticals Earnings Calls
Q1 2025
Beat
$0.0002 (100.21%)
Release date | May 05, 2025 |
EPS estimate | -$0.0700 |
EPS actual | $0.0002 |
EPS Surprise | 100.21% |
Revenue estimate | 149.722M |
Revenue actual | 145.534M |
Revenue Surprise | -2.80% |
Q4 2024
Missed
-$0.130 (-85.71%)
Release date | Feb 24, 2025 |
EPS estimate | -$0.0700 |
EPS actual | -$0.130 |
EPS Surprise | -85.71% |
Revenue estimate | 126.636M |
Revenue actual | 131.534M |
Revenue Surprise | 3.87% |
Q3 2024
Release date | Nov 04, 2024 |
EPS estimate | -$0.0700 |
EPS actual | -$0.0700 |
Revenue estimate | 127.72M |
Revenue actual | 117.085M |
Revenue Surprise | -8.33% |
Q2 2024
Beat
-$0.0600 (68.42%)
Release date | Aug 05, 2024 |
EPS estimate | -$0.190 |
EPS actual | -$0.0600 |
EPS Surprise | 68.42% |
Revenue estimate | 98.32M |
Revenue actual | 109.332M |
Revenue Surprise | 11.20% |
Last 4 Quarters for BioCryst Pharmaceuticals
Below you can see how BCRX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q2 2024
Beat
Release date | Aug 05, 2024 |
Fiscal end date | Jun 30, 2024 |
Price on release | $7.51 |
EPS estimate | -$0.190 |
EPS actual | -$0.0600 |
EPS surprise | 68.42% |
Date | Price |
---|---|
Jul 30, 2024 | $7.40 |
Jul 31, 2024 | $7.28 |
Aug 01, 2024 | $7.11 |
Aug 02, 2024 | $7.02 |
Aug 05, 2024 | $7.51 |
Aug 06, 2024 | $7.87 |
Aug 07, 2024 | $7.44 |
Aug 08, 2024 | $7.97 |
Aug 09, 2024 | $7.63 |
4 days before | 1.49% |
4 days after | 1.60% |
On release day | 4.79% |
Change in period | 3.11% |
Q3 2024
Release date | Nov 04, 2024 |
Fiscal end date | Sep 30, 2024 |
Price on release | $7.35 |
EPS estimate | -$0.0700 |
EPS actual | -$0.0700 |
Date | Price |
---|---|
Oct 29, 2024 | $8.12 |
Oct 30, 2024 | $8.37 |
Oct 31, 2024 | $8.01 |
Nov 01, 2024 | $8.43 |
Nov 04, 2024 | $7.35 |
Nov 05, 2024 | $7.06 |
Nov 06, 2024 | $7.73 |
Nov 07, 2024 | $7.67 |
Nov 08, 2024 | $7.78 |
4 days before | -9.48% |
4 days after | 5.85% |
On release day | -3.95% |
Change in period | -4.19% |
Q4 2024
Missed
Release date | Feb 24, 2025 |
Fiscal end date | Dec 31, 2024 |
Price on release | $8.29 |
EPS estimate | -$0.0700 |
EPS actual | -$0.130 |
EPS surprise | -85.71% |
Date | Price |
---|---|
Feb 18, 2025 | $9.36 |
Feb 19, 2025 | $9.39 |
Feb 20, 2025 | $9.39 |
Feb 21, 2025 | $9.21 |
Feb 24, 2025 | $8.29 |
Feb 25, 2025 | $8.28 |
Feb 26, 2025 | $8.36 |
Feb 27, 2025 | $8.47 |
Feb 28, 2025 | $8.61 |
4 days before | -11.43% |
4 days after | 3.86% |
On release day | -0.121% |
Change in period | -8.01% |
Q1 2025
Beat
Release date | May 05, 2025 |
Fiscal end date | Mar 31, 2025 |
Price on release | $11.03 |
EPS estimate | -$0.0700 |
EPS actual | $0.0002 |
EPS surprise | 100.21% |
Date | Price |
---|---|
Apr 29, 2025 | $8.44 |
Apr 30, 2025 | $8.85 |
May 01, 2025 | $8.71 |
May 02, 2025 | $8.93 |
May 05, 2025 | $11.03 |
May 06, 2025 | $10.27 |
May 07, 2025 | $10.08 |
May 08, 2025 | $9.92 |
May 09, 2025 | $9.97 |
4 days before | 30.69% |
4 days after | -9.61% |
On release day | -6.89% |
Change in period | 18.13% |
BioCryst Pharmaceuticals Earnings Call Transcript Summary of Q1 2025
Summary of Key Points from BioCryst Q1 2025 Earnings Call for Investors:
- Strong Revenue Growth: BioCryst reported quarterly revenue of $145.5 million, primarily driven by ORLADEYO sales of $134.2 million. This represents significant growth and surpasses previous forecasts.
- Guidance Increased: Due to robust performance, the company raised its annual revenue guidance for ORLADEYO to $580-$600 million, reflecting 33%-37% growth from the previous year. The strong sales have allowed BioCryst to accelerate its profitability timeline, now expecting to be profitable for the full year 2025.
- Debt Reduction: BioCryst has successfully paid down debt by $75 million, reducing its outstanding debt to $249 million, which is expected to save approximately $23 million in interest payments.
- Patient Transition to Paid Therapy: The paid patient rate for ORLADEYO jumped to 84%, up from 73.5%, due to improved access under the Inflation Reduction Act (IRA) and enhanced commercial strategies. This substantial increase was achieved more quickly than anticipated.
- Pediatric Formulation Submission: BioCryst has submitted a New Drug Application (NDA) for a pediatric formulation of ORLADEYO, aiming to market it to patients aged 2 to 11. This could significantly enhance revenue by capturing a previously underserved patient segment.
- Pipeline Advancements: The company is progressing on pipeline programs, with plans to begin clinical trials for BCX17725 (for Netherton syndrome) and avoralstat (for diabetic macular edema), both expected to yield initial clinical data by year-end.
- Commercial Strategy: The company's commercial team has improved its execution, particularly in reauthorizations, and is seeing growth in both Medicare and commercial patient segments. The percentage of healthcare providers prescribing ORLADEYO continues to grow.
- Market Potential: There are approximately 10,000 patients in the U.S. with HAE, with only 3,000 having tried ORLADEYO. This indicates significant growth potential, especially with the growing preference for oral medications.
- Long-term Goals: BioCryst remains on track for global annual ORLADEYO revenues to reach approximately $1 billion by 2029, with an emphasis on continued expansion and profitability.
- R&D Focus: Continued emphasis on the research and development pipeline, with specific focus on the rare disease market, aiming for innovative solutions to unmet medical needs.
Conclusion:
BioCryst is showing strong financial performance with increased revenue guidance and quicker transitions of patients to paid statuses for ORLADEYO. The strategic focus on the pediatric market and advancements in its pipeline indicate a robust growth trajectory. Investors should consider these developments as positive indicators for the company’s future performance.
BioCryst Pharmaceuticals Earnings History
Earnings Calendar
FAQ
When is the earnings report for BCRX?
BioCryst Pharmaceuticals (BCRX) has scheduled its earnings report for Aug 04, 2025 before the markets open.
What is the BCRX price-to-earnings (P/E) ratio?
BCRX P/E ratio as of May 09, 2025 (TTM) is -39.38.
What is the BCRX EPS forecast?
The forecasted EPS (Earnings Per Share) for BioCryst Pharmaceuticals (BCRX) for the first fiscal quarter 2025 is -$0.0200.
What are BioCryst Pharmaceuticals's retained earnings?
On its balance sheet, BioCryst Pharmaceuticals reported retained earnings of $145.53 million for the latest quarter ending Mar 31, 2025.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.